Simple contrasts were applied to compare each two different positions in case of statistical significance, which was assumed for p < 0.05. Table 1 shows absolute resting values and relative maximal and stable phase (last 20 s) selleck inhibitor variations to visual stimulation of HR, mean ABP, mean BFV, CVRi, CrCP, and RAP, for PCA and MCA, in supine, sitting and HUT conditions. Regarding only resting values,

repeated-measures ANOVA showed a step increase in HR from supine to HUT positions (p = 0.0001), and of mean ABP from supine to sitting (p = 0.0004), then stabilizing. There was a step decrease in mean BFV of MCA from supine to HUT conditions (p = 0.0004) but for the PCA it seemed to remain constant (p = 0.054) in all positions. Concerning resting data of cerebrovascular resistance models, RAP did not change between different positions, while CVRi and selleck compound CrCP resting values progressively increased from supine to HUT conditions, in both MCA (p = 0.00001 and p = 0.0002, respectively) and PCA (p = 0.0002 and p = 0.00005, respectively), although not reaching statistical significance between sitting and HUT in the case of CVRi

of PCA (p = 0.053). The variation of the parameters with visual stimulation can be visualized in Fig. 1A–F. Mean BFV in the PCA, had similar responses to visual stimulation in all positions (Fig.

1A, maximal p = 0.076; stable phase p = 0.176). All cerebrovascular resistance parameters decreased with visual stimulation in the three positions, but showed different patterns in response to orthostatic challenge: variation of CrCP diminished progressively between supine and HUT (maximal and stable phase p = 0.001); CVRi decreased slightly but significantly more from sitting Amobarbital to HUT positions (maximal p = 0.036; stable phase p = 0.033). RAP seemed to have decreased more in HUT conditions but there was no statistical significance (maximal p = 0.077; stable phase p = 0.188). Although the MCA territory was used as a control, being theoretically a non-stimulated territory, it registered, similarly across all conditions, a small amplitude increment in mean BFV (5–10%), as well as a decrement of CVRi (6–9%), RAP (9–11%) and CrCP (11–17%) at maximal evoked flow phase, which then tended to decrease in the stable phase. For the MCA significant changes were only observed for BFV in maximal (p = 0.035) and CVRi in maximal (p = 0.029) and stable phases (p = 0.043). Regarding systemic hemodynamic data, the changes of ABP and HR with stimulation ranged no more than 4%, with no significant differences between positions, except for maximal increment of ABP which was inferior during HUT compared to supine condition (p = 0.045).